Tri Ri Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Tri Ri Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$3.24M	Buy	+28,088	New	+$3.85M	1.64%	25

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tri Ri Asset Management's NBIX Position: Q3 2024 in Review

Tri Ri Asset Management opened a new position in Neurocrine Biosciences (NBIX) in Q3 2024: 28,088 shares worth $3.24M. The stake represents 1.64% of the portfolio and ranks #25 among its holdings.

574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

Tri Ri Asset Management held 28,088 shares of Neurocrine Biosciences worth $3.24M as of Q3 2024.
Neurocrine Biosciences was a new Tri Ri Asset Management position in Q3 2024.
Neurocrine Biosciences made up 1.64% of Tri Ri Asset Management's portfolio in Q3 2024, its #25 holding.
574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Tri Ri Asset Management's 13F filing for Q3 2024, filed 21 Nov 2024.